Diagnostic Performance of Combining Apparent Diffusion Coefficient and Micro-calcifications to Kaiser Score in Evaluation of BI-RADS 4 Breast Lesions

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Breast cancer is the most commonly diagnosed cancer worldwide and is the leading cause of cancer-related deaths in women. Mammography, breast ultrasonography (US), and breast magnetic resonance imaging (MRI) are essential for the diagnosis and follow-up of breast cancer. The American College of Radiology Breast Imaging- Reporting and Data System (ACR BI-RADS), which is used worldwide, provides the standard terminology for breast imaging (Jajodia et al., 2021). The ACR BI- RADS lexicon categorizes breast imaging findings into seven BIRADS categories of 0, 1, 2, 3, 4(4a, 4b, 4c), 5, and 6 according to the probability of malignancy. Breast imaging findings assigned as BI-RADS 4 require tissue sampling and histopathological examination. However, the likelihood of malignancy of lesions classified as BI-RADS 4 ranges widely, from 3% to 94%. Categorization of lesions according to BI-RADS is related to the experience of the radiologist, with experienced radiologists performing better than inexperienced radiologists

Eligibility
Participation Requirements
Sex: Female
View:

• Patients with BI-RADS 4 lesion.

Locations
Other Locations
Egypt
Mohamed AbdElmoniem
RECRUITING
Al Mansurah
Contact Information
Primary
Mohamed AbdElmoniem
dr.m1993@mans.edu.eg
01014008473
Backup
Maryam Hamdy foaud
Maryamhamdy@mans.edu.eg
01016881450
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2026-01-01
Participants
Target number of participants: 80
Treatments
BI-RADS 4 breast lesions
evaluate the reliability of ADC and micro calcifications (when present) in combination with the Kaiser score in improving the accuracy of the evaluation of BI- RADS 4 lesions and helping avoidance of unnecessary biopsies.
Related Therapeutic Areas
Sponsors
Leads: Mansoura University Hospital

This content was sourced from clinicaltrials.gov